ACARIZAX 12 SQ-HDM oral lyophilisate
*Company:
ALK-Abello LtdStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 22 January 2025
File name
SmPC-IE-ACX-21Jan2025.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated to reflect the change in indication to 5yrs+
Updated on 22 January 2025
File name
Mockup-PiL-IE-ACX-12Dec2024.pdf
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 2 - use in children and adolescents
- Change to section 4 - possible side effects
Updated on 10 May 2022
File name
SPC_IE_PA1255-010-001-Acarizax_Mar2022.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 10 May 2022
File name
PIL_IE_Acarizax_Mar2022.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 09 July 2021
File name
SPC_IE_PA1255-010-001-Acarizax_Jun2021.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
All relevant sections updated to include treatment of allergic rhinitis in adolescents
Updated on 09 July 2021
File name
PIL_IE_Acarizax_Jun2021.pdf
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 2 - use in children and adolescents
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
PIL updated to include treatment of allergic rhinitis in adolescents
Updated on 27 July 2020
File name
SPC_IE_PA1255-010-001-Acarizax_May2020.pdf
Reasons for updating
- Change to section 9 - Date of first authorisation/renewal of the authorisation
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Minor wording changes submitted as part of renewal
Updated on 27 July 2020
File name
PIL_IE_Acarizax_May2020.pdf
Reasons for updating
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Minor wording changes submitted as part of the renewal
Updated on 16 June 2020
File name
SPC_IE_PA1255-010-001-Acarizax_Nov2019.pdf
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 16 June 2020
File name
SPC_IE_PA1255-010-001-Acarizax_Nov2019.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 16 June 2020
File name
PIL_IE_Acarizax_Nov2019.pdf
Reasons for updating
- New PIL for new product
ALK-Abello Ltd
Address:
1 Manor Park, Manor Farm Road, Reading, Berkshire, RG2 0NA, UKMedical Information E-mail:
infouk@alk.netTelephone:
+44 (0)118 903 7940Medical Information Direct Line:
+44 (0)118 903 7940Customer Care direct line:
+44 (0)118 903 7940